

IFW
SPATENT
DOCKET NO. ZAA-003.04

In re Application of:

Kozikowski et al.

Application No: 10/644,645

Filed: August 20, 2003

For: *Bicyclic Metabotropic Glutamate Receptor Ligands*

Art Unit: 1625

Examiner: Aulakh, C.S.

Certificate of Mailing

I hereby certify that this "Information Disclosure Statement" is being deposited with the U. S. Postal Service as First Class Mail with sufficient postage on the date set forth below in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

July 1, 2004
Date of Signature and Mail Deposit

By: Shirine Darvish
Shirine Darvish

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of refs. AA-AB are not required because this application was filed after June 30, 2003 and copies of refs. AC-AM are not provided as they were previously cited by or submitted to the Patent Office in prior patent applications serial nos. 09/118,042, filed July 17, 1998; 09/769,737 filed January 25, 2001; and 10/092,388, filed March 6, 2002; all relied upon for an earlier filing date under 35 U.S.C. §120.

07/09/2004 FFANIA2 00000091 10644645

01 FC:1806

180.00 0P

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) but before the mailing date of a **final action or a notice of allowance** under 37 C.F.R. 1.311, and
 - the requisite Statement is below, **OR**
 - the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- (3) after the mailing date of a **final action or notice of allowance** but before the payment of the **issue fee**, **AND**
 - the requisite Statement is below, **AND**
 - the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.


STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or

- 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Respectfully submitted,



Dana M. Gordon
Attorney/Agent for Applicant(s)
Foley Hoag LLP
155 Seaport Boulevard
Boston, MA 02210-2600

Date: June 30, 2004
Reg. No. 44,719

Tel. No. (617) 832-1000
Fax No. (617) 832-7000

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) ZAA-003.04 (20777-304)	Application Number 10/644,645
		Applicant Kozikowski et al.	
		Filing Date August 20, 2003	Group Art Unit 1625

U.S. PATENT DOCUMENTS

INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	6,204,292	03/20/01	Kozikowski et al.			
AB	6,610,743	08/26/03	Kozikowski et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
AC	EP 0 696 577	14 Feb. 96	Europe				
AD	EP 0 774 454	21 May 97	Europe				
AE	EP 0 774 455	21 May 97	Europe				
AF	EP 0 774 461	21 May 97	Europe				
AG	WO95/15940	15 Jun. 95	PCT				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages Etc.)*

AH	Baker, S.R. et al., The Synthesis of [2.2.1] Bicyclooctane and [3.1.1] Bicycloheptane Based Amino Acids as Constrained Glutamate Analogues. <i>Tetrahed. Lett.</i> Vol. 40:781-784 (1999)
AI	Kozikowski, A.P. et al., "Synthesis and Biology of the Conformationally-Restricted ACPD Analogue, 2-Aminobicyclo[2.1.1] hexane-2,5-Dicarboxylic Acid-1, a Potent mGluR Agonist," <i>J. Med. Chem.</i> , Vol 41:1641-1650 (1998)
AJ	Porter et al., "Growth Inhibition by Methionine Analog Inhibitors of S- Adenosylmethionine Biosynthesis in the Absence of Polyamine Depletion," <i>Biochemical and Biophysical Research Communications</i> , 122(1): 350-357 (July 18, 1994)
AK	Tellier, F. et al., "Synthesis of Conformationally-Constrained Stereospecific Analogs of Glutamic Acid as Antagonists of Metabotropic Receptors," <i>Bioorg. Med. Chem. Lett.</i> , 5:2627-2632 (1995)
AL	Tellier, F. et al., "Synthesis of Conformationally Constrained Stereospecific Analogs of Glutamic Acid as Antagonists of Metabotropic Receptors," <i>Chemical Abstracts</i> , Vol. 124, No. 11, <i>Bioorg. Med. Chem. Lett.</i> , 94, Vol. 5 (22); pp 2627-2632 (March 11 1996)
AM	Tellier, F. et al.; "Synthesis of Conformationally-Constrained Analogs of Glutamic Acid as Structural Probes of Glutamatergic Receptors," <i>Chemical Abstracts</i> , Vol. 124, No. 13, & C.R. Acad. Sci. II, Mec., Phys., Chem. Astron; 95; Vol. 321(9), pp. 385-392 (March 25, 1996)

EXAMINER		DATE CONSIDERED
----------	--	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.